We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Basilea In-Licenses Targeted Cancer Therapy

News   Apr 02, 2015

 
Basilea In-Licenses Targeted Cancer Therapy
 
 
 

RELATED ARTICLES

Targeting Enzyme “Bottleneck” Reveals Novel Anticancer Drug Strategy

News

The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists have now identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.

READ MORE

Compound Created to Block Therapeutic Target in Blood Cancer

News

Researchers have discovered a hyperactive cell signal that contributes to tumor growth in an aggressive blood cancer. The team has also developed an experimental therapeutic "UNC3810A" to block the signal and slow tumor growth.

READ MORE

Increasing the Odds of Synthetic Chemistry Success

News

Chemists show how analyzing previously published chemical reaction data can predict how hypothetical reactions may proceed, narrowing the range of conditions chemists need to explore. Their algorithmic prediction process, which includes aspects of machine learning, can save valuable time and resources in chemical research.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE